Horneff Gerd
Zentrum für Allgemein Pädiatrie und Neonatologie, Asklepios Klinik Sankt Augustin, 53757, Sankt Augustin, Deutschland.
Z Rheumatol. 2019 Sep;78(7):587-598. doi: 10.1007/s00393-019-0646-3.
The introduction of biologics 20 years ago has significantly changed the pharmacotherapy of juvenile idiopathic arthritis. Biologics are among the most successful innovations, not only in rheumatology. In addition to their strong efficacy the rapid onset of improvement , biologics offer an option for prevention of long-term damage and a realistic prospect of remission. This article discusses innovations in biologics and the importance of the latest group for targeted therapy with small molecules in pediatric rheumatology.
20年前生物制剂的引入显著改变了幼年特发性关节炎的药物治疗。生物制剂不仅是风湿病领域最成功的创新之一。除了强大的疗效和迅速的病情改善外，生物制剂还为预防长期损害提供了一种选择，并带来了缓解病情的现实前景。本文讨论了生物制剂的创新以及最新一类生物制剂在儿科风湿病小分子靶向治疗中的重要性。
